Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
7,107 people get GSK articles and Market Currents by email alert.
Get email alerts on GSK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
GlaxoSmithKline Positioning For Clinical Trial Data AdvantageAlan Kotok • Mon, Nov 26, 2012 -
-
-
-
-
-
-
-
-
-
-
Glaxo And Human Genome Have Apparently Seen ReasonStephen Simpson • Mon, Jul 16, 2012
-
Glaxosmithkline plc Q4 2009 Earnings Call TranscriptThu, Feb 4, 2010
-
Human Genome Sciences Inc. Q1 2009 Earnings Call TranscriptWed, Apr 29, 2009 • 1 Comment
-
Human Genome Sciences Inc Q4 2008 Earnings Call TranscriptThu, Feb 26, 2009
-
Human Genome Sciences Inc. Q3 2008 Earnings Call TranscriptThu, Nov 6, 2008
-
Human Genome Sciences Inc. Q2 2008 Earnings Call TranscriptWed, Jul 30, 2008
-
Human Genome Sciences Inc. Q1 2008 Earnings Call TranscriptMon, May 5, 2008
-
at MarketWatch.com (May 13, 2013)
-
at MarketWatch.com (May 13, 2013)
-
PR Newswire (May 10, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 19, 2013)
-
at MarketWatch.com (Apr 18, 2013)
-
at MarketWatch.com (Apr 18, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at CNBC.com (Apr 11, 2013)
-
at CNBC.com (Apr 10, 2013)
GSK vs. ETF Alternatives
Company Description
Human Genome Sciences, Inc. (“HGS” or the “Company”) is a commercially focused biopharmaceutical company advancing toward the market with three products in late-stage development: BENLYSTAtm for systemic lupus erythematosus (“SLE”), ZALBINtm for chronic hepatitis C, and raxibacumab for... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Monday, March 12, 2012, 9:00 AM
Premarket gainers: TUDO +203%. KUTV +33%. ZOLL +24%. YOKU +20%. OREX +15%. FCEL +9%. RENN +9%. DANG +8%. SINA +4%.
Losers: ANTH -51%. HGSI -4%. TLK -3%. Comment! [On the Move] - Wednesday, March 7, 2012, 4:58 PM Eight big drugmakers - ABT, AMGN, AZN, BMY, GSK, MRK, NVS, PFE - are sued by a consumer group claiming the companies’ coupon programs, which cover much of the patient co-payment for hundreds of brand-name prescription medicines, are illegal. 3 Comments [Healthcare]
- Wednesday, March 7, 2012, 10:37 AM Bids are due today for the European part of GlaxoSmithKline's (GSK +0.8%) non-core drugs assets, which could attract £500M ($785M). Those eyeing all or part of the ops include a group comprising Bain Capital and two European partners, as well as Sanofi (SNY), Advent and Avista, Reuters reports. Comment! [Healthcare, M&A]
- Friday, March 2, 2012, 2:26 AM GlaxoSmithKline (GSK) forms a 50-50 JV with Japan's Daiichi Sankyo to bring new vaccines to the Japanese market. The venture, to be called Japan Vaccine Co., is trying to capitalize on Japan's under-developed vaccine market, as the country has traditionally been very slow to approve vaccines commonly used abroad. (PR) Comment! [Global & FX, Healthcare]
- Thursday, March 1, 2012, 4:27 PM Ilumina (ILMN) confirms earlier reports that a federal jury found certain TruSeq sample preparation and cluster generation kits and products infringe on a patent owned by LadaTech, a patent holding company which is jointly owned by GlaxoSmithKline (GSK) and IP Finance. Comment! [Healthcare]
- Wednesday, February 29, 2012, 10:17 AM Morningstar's Ultimate Stock Pickers offer their 10 highest conviction buys: GILD, GSK, RIMM, C, DVN, ITW, SCHW, JNJ, TIF, DHR. Comment! [Quick Ideas]
- Monday, February 27, 2012, 7:06 PM More on Human Genome Sciences (HGSI): Q4 beats estimates across the board. Revenue jumped 113% Y/Y on strong sales of Benlysta and lower R&D expenses. Shares +2.7% AH. Comment! [Healthcare, Earnings, On the Move]
- Monday, February 27, 2012, 4:16 PM Human Genome Sciences (HGSI): Q4 EPS of -$0.41 beats by $0.02. Revenue of $45.5M (+113.6% Y/Y) beats by $3M. Shares +0.7% AH. (PR) Comment! [Earnings, Healthcare]
- Monday, February 27, 2012, 12:10 AM Notable earnings after Monday's close: AWK, CVI, GXP, HGSI, JAZZ, MR, PCLN, SINA, SLXP, SWN, UHS, URS, VNO, WES Comment! [Earnings]
- Sunday, February 26, 2012, 5:35 PM Notable earnings after Monday's close: AWK, CVI, GXP, HGSI, JAZZ, MR, PCLN, SINA, SLXP, SWN, UHS, URS, VNO, WES Comment! [Earnings]
- Thursday, February 23, 2012, 10:46 AM Human Genome (HGSI -1.2%) shares are downgraded to Neutral from Buy at Collins Stewart, which lowers its price target to $10 from $17 after results of its Q4 tracking survey for its Benlysta lupus drug suggest 2012 sales projections are too optimistic. Comment! [Healthcare, On the Move]
- Wednesday, February 22, 2012, 12:59 PM Human Genome (HGSI -6.2%) trades down after RBC cut the shares to Sector Perform on valuation, citing high consensus estimates for Benlysta. Comment! [Healthcare, On the Move]
- Thursday, February 9, 2012, 6:56 AM Vodafone (VOD) follows other firms, moving cash out of Greece "every evening," to guard against an exit from the euro, according to its CFO Andy Halford. GlaxoSmithKline (GSK) takes it a step further, moving its cash from all of Europe (save Germany) into the U.K. each day. Comment! [Global & FX, Financials]
- Wednesday, February 8, 2012, 11:05 AM Glaxo SmithKline (GSK -1%) says it's been repatriating large sums of cash out of eurozone countries for months, converting euros back daily to the U.K. in sterling. The drug maker says it's doing so out of fear the debt crisis may take a turn for the worse. "You don't have money in banks you're nervous about," CEO Sir Andrew Witty remarked at the company's annual presentation in London. 1 Comment [Healthcare, Global & FX]
-
Tuesday, February 7, 2012, 9:00 AM
Premarket gainers: CSTR +19%. CVM +11%. SPF +10%. SHPGY +5%. S +5%. AMLN +4%. NBG +4%. PRGO +3%. HGSI +3%. CLF +3%. CHU +3%.
Losers: NSU -22%. CFX -10%. ASTX -10%. BPAX -6%. LPL -5%. THLD -5%. SBH -4%. ALU -4%. ZOLT -4%. FRO -3%. VHPM -3%. CTIC -3%. Comment! [On the Move] - Tuesday, February 7, 2012, 7:40 AM GlaxoSmithKline (GSK): Q4 EPS of 0.28 pence misses by 0.02. Revenue of £6.97B (-3% Y/Y). Shares -2.5% premarket. (PR) Comment! [Earnings, Healthcare, On the Move]
-
- View all 3 replies
-
-
Michael Stuart: Keno, lottery, maybe scratchers? Either way, I've pissed a C-note away in far more stupid ways in the market ;)
-
- View all 8 replies
-
-
-
- View all 2 replies
-
-
mbill: I believe the rumored takeover bid is just a rumor and not likely, but the price looks reasonable.
-
Michael Stuart
Bought 2 GSK $14 JAN calls @$1.80. Not expecting rumors to pan out, but feel it's a "lottery ticket" situation. - View all 2 replies
-
-
Michael Stuart: And now green on the calls, despite commissions and a massive bid/ask spread ;)
-
Asif Suria
GSK could launch a $25 a share cash offer for Maryland-based Human Genome Sciences $GSK $GSK - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
GSK - 72% Barchart technical sell signal - 9.28% off its recent high - Relative Strength Index 42.16% and falling - View all 0 replies
-
Justin M. Hall
8/6/11 12A ET: (ONXX, ITMN, GSK, QGEN, GPRO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg - View all 0 replies
-
- View all 0 replies
LATEST REPLIES